On Monday, UroGen Pharma Ltd (NASDAQ: URGN) was 4.82% up from the session before settling in for the closing price of $21.8. A 52-week range for URGN has been $3.42 – $30.00.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 10.39%. When this article was written, the company’s average yearly earnings per share was at -7.30%. With a float of $38.70 million, this company’s outstanding shares have now reached $46.78 million.
UroGen Pharma Ltd (URGN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward UroGen Pharma Ltd stocks. The insider ownership of UroGen Pharma Ltd is 17.32%, while institutional ownership is 93.16%. The most recent insider transaction that took place on Nov 19 ’25, was worth 250,000. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $25.00, taking the stock ownership to the 139,025 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Officer proposed sale 10,000 for $25.00, making the entire transaction worth $250,005.
UroGen Pharma Ltd (URGN) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.8 earnings per share (EPS) during the time that was less than consensus figure (set at -0.72) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.30% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
You can see what UroGen Pharma Ltd (URGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.46, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
The latest stats from [UroGen Pharma Ltd, URGN] show that its last 5-days average volume of 0.99 million was inferior to 1.42 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 14.10%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 49.43%, which indicates a significant increase from 16.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.59 in the past 14 days, which was higher than the 1.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.63, while its 200-day Moving Average is $15.54. Now, the first resistance to watch is $23.38. This is followed by the second major resistance level at $23.91. The third major resistance level sits at $24.90. If the price goes on to break the first support level at $21.86, it is likely to go to the next support level at $20.87. The third support level lies at $20.34 if the price breaches the second support level.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
There are 46,809K outstanding shares of the company, which has a market capitalization of 1.07 billion. As of now, sales total 90,400 K while income totals -126,870 K. Its latest quarter income was 27,480 K while its last quarter net income were -33,350 K.
